AUTL · Autolus Therapeutics plc
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|---|
| $117.39M | $75.39M | $10.12M | $1.7M | — | — | — | $2.91M | $1.41M | |
| $99.01M | $96.37M | $11.39M | $0 | — | — | — | — | — | |
| $18.38M | -$20.98M | -$1.27M | $1.7M | — | — | — | — | — | |
| — | -27.83% | -12.52% | 100% | — | — | — | — | — | |
| $112.63M | $117.69M | $138.44M | $130.48M | $117.35M | $110.84M | $134.89M | $105.42M | $36.15M | |
| $83.14M | — | — | $46.75M | $31.9M | $31.87M | $34.97M | $39.45M | $22.79M | |
| $153.19M | $131.87M | $101.72M | $46.75M | — | — | — | — | — | |
| $1.92M | $1.52M | $162K | $0 | $65K | $90K | $91K | $47K | — | |
| — | $8.3M | $7.55M | $6.57M | $7.42M | $8.46M | $5.66M | $4.61M | — | |
| — | $2.4M | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | $57.53M | |
| -$247.44M | -$270.54M | -$241.43M | -$179.7M | -$143.41M | -$141.05M | -$168.15M | -$146.06M | — | |
| — | -358.87% | -2385.63% | -10583.1% | — | — | — | -5022.83% | — | |
| — | -$262.25M | -$233.87M | -$173.14M | -$135.99M | -$132.59M | -$162.49M | -$141.45M | — | |
| $41.81M | $36.67M | $9.29M | $45.07M | $8.91M | $1.11M | $0 | $0 | — | |
| $11.96M | $18.98M | $32.36M | $13.51M | $1.71M | $262K | $536K | $2.54M | $1.53M | |
| -$32.04M | -$15.01M | $22.29M | -$28.7M | -$5.16M | -$988K | $1.89M | $7.06M | $5.5M | |
| -$279.48M | -$285.56M | -$219.13M | -$208.4M | -$148.57M | -$142.04M | -$166.26M | -$139.01M | -$52.03M | |
| $678K | $1.97M | $1.53M | -$19K | $272K | $58K | -$24.16M | -$15.16M | -$7.28M | |
| -$280.16M | -$287.53M | -$220.66M | -$208.38M | -$148.84M | -$142.1M | -$142.09M | -$123.85M | -$44.75M | |
| — | -381.4% | -2180.45% | -12272.26% | — | — | — | -4258.91% | -3180.6% | |
| -$280.16M | -$287.53M | -$220.66M | -$208.38M | -$148.84M | -$142.1M | -$142.09M | — | — | |
| -$287.12M | -$263.71M | -$220.84M | -$198.48M | -$179.17M | -$144.81M | -$139.26M | -$117.05M | -$50.82M | |
| USD/shares | — | -$1.08 | -$0.86 | -$1.20 | -$1.57 | -$1.97 | -$2.76 | -$2.88 | — |
| USD/shares | — | -$1.08 | -$0.86 | -$1.20 | -$1.57 | -$1.97 | -$2.76 | -$2.88 | — |
| shares | — | 266.14M | 255.16M | 173.94M | 94.99M | 72.08M | 51.56M | 43.07M | 31.56M |
| shares | — | 266.14M | 255.16M | 173.94M | 94.99M | 72.08M | 51.56M | 43.07M | 31.56M |
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 317 similar-size Biotechnology companies (of 545 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 |
|---|---|---|
| Reportable Segment | $75,388,000 | $10,120,000 |
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| United States | $75,338,000 | $0 | $1,352,000 | $6,194,000 | $1,507,000 | $0 | $0 |
| Europe | $50,000 | $10,120,000 | $0 | — | — | — | — |
| United Kingdom | — | — | $346,000 | $0 | $0 | $242,000 | $0 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Product | $74,318,000 | $0 | $0 | — | — | — | — |
| License | $1,070,000 | $10,120,000 | $1,698,000 | $6,194,000 | $1,507,000 | $242,000 | $0 |
| Royalty | $0 | $0 | $0 | $0 | $0 | $0 | — |
| Grant | — | — | $0 | $166,000 | $823,000 | $1,473,000 | $2,908,000 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Reportable Segment | -$270,544,000 | -$241,426,000 | -$179,701,000 |
Operating Margin by Segment (%)
| Component | FY2025 | FY2024 |
|---|---|---|
| Reportable Segment | -358.9% | -2385.6% |